EyePoint Pharmaceuticals, Inc. (EYPT)
EYPT Stock Price Chart
Explore EyePoint Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze EYPT price movements and trends.
EYPT Company Profile
Discover essential business fundamentals and corporate details for EyePoint Pharmaceuticals, Inc. (EYPT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Jan 2005
Employees
165.00
Website
https://eyepointpharma.comCEO
Jay S. Duker
Description
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
EYPT Financial Timeline
Browse a chronological timeline of EyePoint Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.77, while revenue estimate is $3.33M.
Earnings released on 6 Aug 2025
EPS came in at -$0.85 falling short of the estimated -$0.67 by -26.87%, while revenue for the quarter reached $5.33M , beating expectations by +29.22%.
Earnings released on 7 May 2025
EPS came in at -$0.65 matching the estimated -$0.65, while revenue for the quarter reached $24.45M , beating expectations by +258.36%.
Earnings released on 5 Mar 2025
EPS came in at -$0.64 falling short of the estimated -$0.54 by -18.52%, while revenue for the quarter reached $11.59M , beating expectations by +41.54%.
Earnings released on 7 Nov 2024
EPS came in at -$0.54 falling short of the estimated -$0.48 by -12.50%, while revenue for the quarter reached $10.52M , missing expectations by -0.34%.
Earnings released on 7 Aug 2024
EPS came in at -$0.58 falling short of the estimated -$0.55 by -5.45%, while revenue for the quarter reached $9.48M , missing expectations by -1.18%.
Earnings released on 8 May 2024
EPS came in at -$0.55 falling short of the estimated -$0.34 by -61.76%, while revenue for the quarter reached $11.68M , beating expectations by +17.07%.
Earnings released on 7 Mar 2024
EPS came in at -$0.33 surpassing the estimated -$0.60 by +45.00%, while revenue for the quarter reached $14.03M , beating expectations by +57.62%.
Earnings released on 1 Nov 2023
EPS came in at -$0.33 surpassing the estimated -$0.62 by +46.77%, while revenue for the quarter reached $15.20M , beating expectations by +74.54%.
Earnings released on 2 Aug 2023
EPS came in at -$0.61 falling short of the estimated $0.41 by -248.78%, while revenue for the quarter reached $9.11M , missing expectations by -82.46%.
Earnings released on 3 May 2023
EPS came in at -$0.56 surpassing the estimated -$0.65 by +13.85%, while revenue for the quarter reached $7.68M , beating expectations by +3.41%.
Earnings released on 2 Mar 2023
EPS came in at -$0.61 surpassing the estimated -$0.63 by +3.17%, while revenue for the quarter reached $10.53M , beating expectations by +1.25%.
Earnings released on 2 Nov 2022
EPS came in at -$0.49 surpassing the estimated -$0.70 by +30.00%, while revenue for the quarter reached $10.01M , missing expectations by -8.37%.
Earnings released on 3 Aug 2022
EPS came in at -$0.52 surpassing the estimated -$0.57 by +8.77%, while revenue for the quarter reached $11.57M , beating expectations by +6.45%.
Earnings released on 4 May 2022
EPS came in at -$0.52 falling short of the estimated -$0.50 by -4.00%, while revenue for the quarter reached $9.29M , missing expectations by -6.00%.
Earnings released on 3 Mar 2022
EPS came in at -$0.59 falling short of the estimated -$0.50 by -18.00%, while revenue for the quarter reached $11.54M , beating expectations by +17.90%.
Earnings released on 3 Nov 2021
EPS came in at -$0.58 falling short of the estimated -$0.47 by -23.40%, while revenue for the quarter reached $9.06M , missing expectations by -7.94%.
Earnings released on 4 Aug 2021
EPS came in at -$0.35 surpassing the estimated -$0.45 by +22.22%, while revenue for the quarter reached $9.01M , meeting expectations.
Earnings released on 5 May 2021
EPS came in at -$0.50 surpassing the estimated -$0.53 by +5.66%, while revenue for the quarter reached $7.32M , missing expectations by -9.14%.
Earnings released on 4 Mar 2021
EPS came in at -$1.01 falling short of the estimated $0.45 by -324.44%, while revenue for the quarter reached $7.13M , missing expectations by -54.67%.
Stock split effective on 9 Dec 2020
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 5 Nov 2020
EPS came in at -$0.30 falling short of the estimated -$0.10 by -200.00%, while revenue for the quarter reached $15.70M , beating expectations by +284.30%.
EYPT Stock Performance
Access detailed EYPT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.